Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jun Li, Dan Liao, Fujue Wang, Zhongwang Wang, Yueshan Li, Yu Xiong & Ting Niu. (2022) RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo. Leukemia & Lymphoma 63:5, pages 1167-1179.
Read now
Read now
Marie-Anne Hospital, Alexa S Green, Thiago T Maciel, Ivan C Moura, Anskar Y Leung, Didier Bouscary & Jerome Tamburini. (2017) FLT3 inhibitors: clinical potential in acute myeloid leukemia. OncoTargets and Therapy 10, pages 607-615.
Read now
Read now
Tor Henrik Tvedt, Ina Nepstad & Øystein Bruserud. (2017) Antileukemic effects of midostaurin in acute myeloid leukemia – the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells. Expert Opinion on Investigational Drugs 26:3, pages 343-355.
Read now
Read now
Catherine J. Lee, Parveen Shiraz & Lori Muffly. (2017) Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leukemia & Lymphoma 58:3, pages 516-527.
Read now
Read now
Sara Mongiorgi, Carlo Finelli, Yong Ryoul Yang, Cristina Clissa, James A. McCubrey, Anna Maria Billi, Lucia Manzoli, Pann-Ghill Suh, Lucio Cocco & Matilde Y. Follo. (2016) Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes. Expert Opinion on Therapeutic Targets 20:6, pages 677-687.
Read now
Read now
Articles from other publishers (51)
Hamidreza Zalpoor, Maryam Bakhtiyari, Abdullatif Akbari, Fatemeh Aziziyan, Hooriyeh Shapourian, Mahsa Liaghat, Zahra Zare-Badie, Sheida Yahyazadeh, Vahideh Tarhriz & Mazdak Ganjalikhani-Hakemi. (2022) Potential role of autophagy induced by FLT3-ITD and acid ceramidase in acute myeloid leukemia chemo-resistance: new insights. Cell Communication and Signaling 20:1.
Crossref
Crossref
Fangli Chen, Emilia Licarete, Xue Wu, Daniela Petrusca, Callista Maguire, Max Jacobsen, Austyn Colter, George E. Sandusky, Magdalena Czader, Maegan L. Capitano, James P. Ropa, H. Scott Boswell, Fabrizio Carta, Claudiu T. Supuran, Brian Parkin, Melissa L. Fishel & Heiko Konig. (2021) Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions. Journal of Cellular and Molecular Medicine 25:24, pages 11039-11052.
Crossref
Crossref
Bartholomew J. Eisfelder, Caner Saygin, Joseph Wynne, Margaret W. Colton, Mariafausta Fischietti, Elspeth M. Beauchamp, Jason X. Cheng, Olatoyosi Odenike, Gail Roboz, Houda Alachkar & Wendy Stock. (2021) OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer Journal 11:3.
Crossref
Crossref
Hanane Djamai, Jeannig Berrou, Mélanie Dupont, Anna Kaci, Jan Erik Ehlert, Holger Weber, André Baruchel, Fabrice Paublant, Renaud Prudent, Claude Gardin, Hervé Dombret & Thorsten Braun. (2021) Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells. Leukemia Research 100, pages 106490.
Crossref
Crossref
Nur Şebnem ERSÖZ & Aysun ADAN. (2020) Cytotoxic Effects of Resveratrol and Its Combinations with Ceramide Metabolism Inhibitors on FLT3 Positive Acute Myeloid LeukemiaResveratrol ve Seramid Metabolizması Enzim İnhibitörleri İle Kombinasyonlarının FLT3 Pozitif Akut Miyeloid Lösemideki Sitotoksik Etkileri. Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi 13:3, pages 1205-1216.
Crossref
Crossref
Xiaoli Hu, Jiayi Cai, Jianyi Zhu, Wenjing Lang, Jihua Zhong, Hua Zhong & Fangyuan Chen. (2020) Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress. Cancer Cell International 20:1.
Crossref
Crossref
Eirik Solum, Trond Vidar Hansen, Reidun Aesoy & Lars Herfindal. (2020) New CDK8 inhibitors as potential anti-leukemic agents – Design, synthesis and biological evaluation. Bioorganic & Medicinal Chemistry 28:10, pages 115461.
Crossref
Crossref
Mengyuan Lyu, Hongyan Liao, Xiao Shuai, Yongmei Jin, Jun Su & Qin Zheng. (2020) The prognosis predictive value of FMS-like tyrosine kinase 3-internal tandem duplications mutant allelic ratio (FLT3-ITD MR) in patients with acute myeloid leukemia detected by GeneScan. Gene 726, pages 144195.
Crossref
Crossref
Heather R. Dorman, David Close, Bentley M. Wingert, Carlos J. Camacho, Paul A. Johnston & Thomas E. Smithgall. (2019) Discovery of Non-peptide Small Molecule Allosteric Modulators of the Src-family Kinase, Hck. Frontiers in Chemistry 7.
Crossref
Crossref
Nessar Ahmad Azrakhsh, Patrycja Mensah-glanowska, Kristoffer Sand & Astrid Olsnes Kittang. (2019) Targeting Immune Signaling Pathways in Clonal Hematopoiesis. Current Medicinal Chemistry 26:28, pages 5262-5277.
Crossref
Crossref
Ralf Buettner, Le Xuan Truong Nguyen, Bijender Kumar, Corey Morales, Chao Liu, Lisa S. Chen, Tea Pemovska, Timothy W. Synold, Joycelynne Palmer, Ryan Thompson, Ling Li, Dinh Hoa Hoang, Bin Zhang, Lucy Ghoda, Claudia Kowolik, Mika Kontro, Calum Leitch, Krister Wennerberg, Xiaochun Yu, Ching‐Cheng Chen, David Horne, Varsha Gandhi, Vinod Pullarkat, Guido Marcucci & Steven T. Rosen. (2019) 8‐chloro‐adenosine activity in FLT3‐ITD acute myeloid leukemia. Journal of Cellular Physiology 234:9, pages 16295-16303.
Crossref
Crossref
Xin Tang, Jesse DrotarKeji Li, Cullen D. Clairmont, Anna Sophie BrummAustin J. Sullins, Hao WuXiaoxiao Shawn LiuJinhua WangNathanael S. GrayMriganka Sur & Rudolf Jaenisch. (2019)
Pharmacological enhancement of
KCC2
gene expression exerts therapeutic effects on human Rett syndrome neurons and
Mecp2
mutant mice
. Science Translational Medicine 11:503.
Crossref
Crossref
Catherine J. Lee, Bipin N. Savani, Mohamad Mohty, Norbert C. Gorin, Myriam Labopin, Annalisa Ruggeri, Christoph Schmid, Frédéric Baron, Jordi Esteve, Sebastian Giebel, Fabio Ciceri & Arnon Nagler. (2018) Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation 54:4, pages 519-530.
Crossref
Crossref
Tapan Mahendra Kadia, Hagop M. Kantarjian & Marina Konopleva. (2019) Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy. Oncotarget 10:12, pages 1250-1265.
Crossref
Crossref
Dilana Staudt, Heather Murray, Tabitha McLachlan, Frank Alvaro, Anoop Enjeti, Nicole Verrills & Matthew Dun. (2018) Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance. International Journal of Molecular Sciences 19:10, pages 3198.
Crossref
Crossref
Rui Wang, Ying Li, Ping Gong, Janice Gabrilove, Samuel Waxman & Yongkui Jing. (2018) Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells. Molecular Cancer Therapeutics 17:9, pages 1871-1880.
Crossref
Crossref
Eman Z. Kandeel, Ghada El Sayed, Nahla Elsharkawy, Dalia Negm Eldin, Hanan R. Nassar, Dalia Ibrahiem, Randa Amin, Marwa Hanafi, Mohamed Khalil & Azza Kamel. (2018) Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients. Clinical Lymphoma Myeloma and Leukemia 18:8, pages 541-547.
Crossref
Crossref
Fu Li, May Kung Sutherland, Changpu Yu, Roland B. Walter, Lori Westendorf, John Valliere-Douglass, Lucy Pan, Ashley Cronkite, Django Sussman, Kerry Klussman, Michelle Ulrich, Martha E. Anderson, Ivan J. Stone, Weiping Zeng, Mechthild Jonas, Timothy S. Lewis, Maitrayee Goswami, Sa A. Wang, Peter D. Senter, Che-Leung Law, Eric J. Feldman & Dennis R. Benjamin. (2018) Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia. Molecular Cancer Therapeutics 17:2, pages 554-564.
Crossref
Crossref
Jennifer N. Moloney, Ashok Kumar Jayavelu, Joanna Stanicka, Sarah L. Roche, Rebecca L. O’Brien, Sebastian Scholl, Frank-D. Böhmer & Thomas G. Cotter. (2017) Nuclear membrane-localised NOX4D generates pro-survival ROS in FLT3-ITD-expressing AML. Oncotarget 8:62, pages 105440-105457.
Crossref
Crossref
Hubert Hackl, Ksenia Astanina & Rotraud Wieser. (2017) Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
J. Kyle Bruner, Hayley S. Ma, Li Li, Alice Can Ran Qin, Michelle A. Rudek, Richard J. Jones, Mark J. Levis, Keith W. Pratz, Christine A. Pratilas & Donald Small. (2017) Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies. Cancer Research 77:20, pages 5554-5563.
Crossref
Crossref
H-Q Ju, G Zhan, A Huang, Y Sun, S Wen, J Yang, W-h Lu, R-h Xu, J Li, Y Li, G Garcia-Manero, P Huang & Y Hu. (2017) ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition. Leukemia 31:10, pages 2143-2150.
Crossref
Crossref
Alfred Chung, Yanli Hou, Robert S. Ohgami, Ann Von Gehr, Dianna G. Fisk, Krishna M. Roskin, Xu Li, Linda Gojenola, Charles D. Bangs, Daniel A. Arber, Andrew Z. Fire, Athena M. Cherry, James L. Zehnder, Jason Gotlib & Jason D. Merker. (2017) A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. Cancer Genetics 216-217, pages 10-15.
Crossref
Crossref
Masamichi Mori, Naoki Kaneko, Yoko Ueno, Masaki Yamada, Ruriko Tanaka, Rika Saito, Itsuro Shimada, Kenichi Mori & Sadao Kuromitsu. (2017) Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Investigational New Drugs 35:5, pages 556-565.
Crossref
Crossref
Mrinal M Patnaik. (2017) Midostaurin for the treatment of acute myeloid leukemia. Future Oncology 13:21, pages 1853-1871.
Crossref
Crossref
Panpan Hou, Chao Wu, Yuchen Wang, Rui Qi, Dheeraj Bhavanasi, Zhixiang Zuo, Cedric Dos Santos, Shuliang Chen, Yu Chen, Hong Zheng, Hong Wang, Alexander Perl, Deyin Guo & Jian Huang. (2017) A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. Cancer Research 77:16, pages 4402-4413.
Crossref
Crossref
Sarah Etheridge. (2017) Patients in Focus: What’s Relevant for Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia?. EMJ Hematology, pages 53-61.
Crossref
Crossref
Mark C. Weir, Sabine Hellwig, Li Tan, Yao Liu, Nathanael S. Gray & Thomas E. Smithgall. (2017) Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth. PLOS ONE 12:7, pages e0181178.
Crossref
Crossref
Jonathan Metts, Heath L. Bradley, Zhengqi Wang, Neil P. Shah, Reuben Kapur, Jack L. Arbiser & Kevin D. Bunting. (2017) Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells. Scientific Reports 7:1.
Crossref
Crossref
Xiaochu Ma, Jie Zhou, Changhao Wang, Brandon Carter-Cooper, Fan Yang, Elizabeth Larocque, Jonathan Fine, Genichiro Tsuji, Gaurav Chopra, Rena G. Lapidus & Herman O. Sintim. (2017) Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach. ACS Medicinal Chemistry Letters 8:5, pages 492-497.
Crossref
Crossref
Emily-Marie Latuske, Hauke Stamm, Marianne Klokow, Gabi Vohwinkel, Jana Muschhammer, Carsten Bokemeyer, Manfred Jücker, Maxim Kebenko, Walter Fiedler & Jasmin Wellbrock. (2017) Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia. Oncotarget 8:17, pages 29187-29201.
Crossref
Crossref
A Staffas, L S Arabanian, S Y Wei, A Jansson, S Ståhlman, P Johansson, L Fogelstrand, J Cammenga, F Kuchenbauer & L Palmqvist. (2016) Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice. Oncogene 36:11, pages 1516-1524.
Crossref
Crossref
Maximilian Fleischmann, Ulf Schnetzke, Karin G. Schrenk, Volker Schmidt, Herbert G. Sayer, Inken Hilgendorf, Andreas Hochhaus & Sebastian Scholl. (2016) Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Journal of Cancer Research and Clinical Oncology 143:2, pages 337-345.
Crossref
Crossref
Claudia M. Kowolik, Min Lin, Jun Xie, Larry E. Overman & David A. Horne. (2016)
NT1721, a novel epidithiodiketopiperazine, exhibits potent
in vitro
and
in vivo
efficacy against acute myeloid leukemia
. Oncotarget 7:52, pages 86186-86197.
Crossref
Crossref
Sabine Kayser & Mark J Levis. (2016)
Are FLT3 inhibitors likely to improve
FLT3
-mutated acute myeloid leukemia in the foreseeable future?
. International Journal of Hematologic Oncology 5:4, pages 123-126.
Crossref
Crossref
Phillip M. Garfin & Eric J. Feldman. (2016) Antibody-Based Treatment of Acute Myeloid Leukemia. Current Hematologic Malignancy Reports 11:6, pages 545-552.
Crossref
Crossref
Marianne Jarfelt, Niels H. Andersen & Henrik Hasle. (2016) Is it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?. British Journal of Haematology 175:4, pages 577-587.
Crossref
Crossref
A. ?sterroos, M. Kashif, C. Haglund, K. Blom, M. H?glund, C. Andersson, M.G. Gustafsson, A. Eriksson & R. Larsson. (2016) Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia. Biochemical Pharmacology 118, pages 40-49.
Crossref
Crossref
I De Kouchkovsky & M Abdul-Hay. (2016) ‘Acute myeloid leukemia: a comprehensive review and 2016 update’. Blood Cancer Journal 6:7, pages e441-e441.
Crossref
Crossref
Amin Huang, Huai-Qiang Ju, Kaiyan Liu, Guilian Zhan, Daolu Liu, Shijun Wen, Guillermo Garcia-Manero, Peng Huang & Yumin Hu. (2016) Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation. Cancer Letters 377:2, pages 149-157.
Crossref
Crossref
Danielle Shafer & Steven Grant. (2016) Update on rational targeted therapy in AML. Blood Reviews 30:4, pages 275-283.
Crossref
Crossref
Iris Z. UrasGina J. WalterRuth ScheicherFlorian BelluttiMichaela Prchal-MurphyAnca S. TiganPeter ValentFlorian H. HeidelStefan Kubicek, Claudia SchollStefan Fröhling & Veronika Sexl. (2016) Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood 127:23, pages 2890-2902.
Crossref
Crossref
E Chang, S Ganguly, T Rajkhowa, C D Gocke, M Levis & H Konig. (2015) The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells. Leukemia 30:5, pages 1025-1032.
Crossref
Crossref
Harinder Gill, Anskar Leung & Yok-Lam Kwong. (2016) Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy. International Journal of Molecular Sciences 17:4, pages 440.
Crossref
Crossref
Asim Khwaja, Magnus Bjorkholm, Rosemary E. Gale, Ross L. Levine, Craig T. Jordan, Gerhard Ehninger, Clara D. Bloomfield, Eli Estey, Alan Burnett, Jan J. Cornelissen, David A. Scheinberg, Didier Bouscary & David C. Linch. (2016) Acute myeloid leukaemia. Nature Reviews Disease Primers 2:1.
Crossref
Crossref
Harinder Gill, Anskar YH Leung & Yok-Lam Kwong. (2016) Molecularly targeted therapy in acute myeloid leukemia. Future Oncology 12:6, pages 827-838.
Crossref
Crossref
David GrimwadeAdam IveyBrian J. P. Huntly. (2016) Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood 127:1, pages 29-41.
Crossref
Crossref
Timea Simon, Ciprian Tomuleasa, Anca Bojan, Ioana Berindan-Neagoe, Sanda Boca & Simion Astilean. (2015) Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia. Nanoscale Research Letters 10:1.
Crossref
Crossref
X Peng, M Dong, L Ma, X-E Jia, J Mao, C Jin, Y Chen, L Gao, X Liu, K Ma, L Wang, T Du, Y Jin, Q Huang, K Li, L I Zon, T Liu, M Deng, Y Zhou, X Xi, Y Zhou & S Chen. (2015) A point mutation of zebrafish c-cbl gene in the ring finger domain produces a phenotype mimicking human myeloproliferative disease. Leukemia 29:12, pages 2355-2365.
Crossref
Crossref
Monica R. Muppidi, Scott Portwood, Elizabeth A. Griffiths, James E. Thompson, Laurie A. Ford, Craig W. Freyer, Meir Wetzler & Eunice S. Wang. (2015) Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 15, pages S73-S79.
Crossref
Crossref
Nestor Ramos, Clifton Mo, Judith Karp & Christopher Hourigan. (2015) Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. Journal of Clinical Medicine 4:4, pages 665-695.
Crossref
Crossref